{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T19:40:08Z","timestamp":1749325208958,"version":"3.41.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>Huntington disease is a rare genetic disorder characterized by motor, cognitive, and psychiatric impairments. Although the typical patient has a positive family history and initially presents with chorea between ages 30 and 50 years, some patients do not have a typical presentation. Healthcare providers should know when to refer patients to neurology for testing for Huntington disease. The earlier the diagnosis is made, the earlier the patient and patient's family can receive education about the expected disease trajectory. A multidisciplinary approach is required to mitigate symptoms as the disease progresses. Although no cure exists, ongoing research is targeting genotypic abnormalities in hopes of finding a permanent treatment for Huntington disease.<\/jats:p>","DOI":"10.1097\/01.jaa.0000735740.95438.60","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T16:16:10Z","timestamp":1616084170000},"page":"26-31","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["On the hunt for a cure"],"prefix":"10.1097","volume":"34","author":[{"given":"Jennifer","family":"de la Cruz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"9","key":"R1-20250607","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/mds.25075","article-title":"The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis","volume":"27","author":"Pringsheim","year":"2012","journal-title":"Mov Disord"},{"issue":"6","key":"R2-20250607","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/mds.27653","article-title":"Huntington's disease in the United States: variation by demographic and socioeconomic factors","volume":"34","author":"Bruzelius","year":"2019","journal-title":"Mov Disord"},{"issue":"2","key":"R3-20250607","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3233\/JHD-170247","article-title":"What do we know about late onset Huntington's disease","volume":"6","author":"Chaganti","year":"2017","journal-title":"J Huntingtons Dis"},{"issue":"11","key":"R4-20250607","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/mds.26001","article-title":"Genetic modifiers of Huntington's disease","volume":"29","author":"Gusella","year":"2014","journal-title":"Mov Disord"},{"author":"Wheelock","article-title":"Juvenile Huntington's disease","key":"R5-20250607"},{"issue":"5","key":"R6-20250607","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/ejhg.2012.200","article-title":"European Molecular Genetic Quality Network (EMQN). EMQN\/CMGS best practice guidelines for the molecular genetic testing of Huntington disease","volume":"21","author":"Losekoot","year":"2013","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"R8-20250607","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00415-016-8310-1","article-title":"Exercise effects in Huntington disease","volume":"264","author":"Frese","year":"2017","journal-title":"J Neurol"},{"key":"R9-20250607","first-page":"99","article-title":"Management of late stage HD","author":"Nance","year":"2011","journal-title":"A Physician's Guide to the Management of Huntington's Disease"},{"key":"R10-20250607","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2147\/DDDT.S138828","article-title":"Review of deutetrabenazine: a novel treatment for chorea associated with Huntington's disease","volume":"12","author":"Dean","year":"2018","journal-title":"Drug Des Devel Ther"},{"issue":"21","key":"R11-20250607","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.2174\/138161206777698693","article-title":"Pharmacological management of Huntington's disease: an evidence-based review","volume":"12","author":"Bonelli","year":"2006","journal-title":"Curr Pharm Des"},{"issue":"1","key":"R12-20250607","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3233\/JHD-190001","article-title":"Huntington's disease clinical trials corner: January 2019","volume":"8","author":"Rodrigues","year":"2019","journal-title":"J Huntingtons Dis"},{"issue":"2","key":"R13-20250607","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1055\/s-0029-1213731","article-title":"Movement disorders caused by medical disease","volume":"29","author":"Barton","year":"2009","journal-title":"Semin Neurol"},{"issue":"947","key":"R14-20250607","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1136\/pgmj.2004.019356","article-title":"Chorea and related disorders","volume":"80","author":"Bhidayasiri","year":"2004","journal-title":"Postgrad Med J"},{"issue":"7","key":"R15-20250607","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1474-4422(06)70494-X","article-title":"Seminar on choreas","volume":"5","author":"Cardoso","year":"2006","journal-title":"Lancet Neurol"},{"issue":"4","key":"R16-20250607","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/WCO.0b013e3283632d90","article-title":"Huntington's disease and Huntington's disease-like syndromes: an overview","volume":"26","author":"G\u00f6vert","year":"2013","journal-title":"Curr Opin Neurol"},{"issue":"4","key":"R17-20250607","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/mdc3.12312","article-title":"Huntington's disease, Huntington's disease look-alikes, and benign hereditary chorea: what's new","volume":"3","author":"Schneider","year":"2016","journal-title":"Mov Disord Clin Pract"},{"issue":"4","key":"R18-20250607","first-page":"1001","article-title":"Chorea","volume":"25","author":"Termsarasab","year":"2019","journal-title":"Continuum (Minneap Minn)"},{"issue":"11","key":"R19-20250607","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1093\/hmg\/ddw095","article-title":"Enhanced mitochondrial biogenesis ameliorates disease phenotype in a full-length mouse model of Huntington's disease","volume":"25","author":"Chandra","year":"2016","journal-title":"Hum Mol Genet"},{"issue":"1","key":"R20-20250607","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nm.4003","article-title":"PPAR delta repression in Huntington's disease and its essential role in CNS translate into a potent agonist therapy","volume":"22","author":"Dickey","year":"2016","journal-title":"Nat Med"},{"issue":"1","key":"R21-20250607","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jama.2016.8655","article-title":"Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial","volume":"316","author":"Frank","year":"2016","journal-title":"JAMA"},{"issue":"3","key":"R22-20250607","doi-asserted-by":"crossref","first-page":"217","DOI":"10.5607\/en.2018.27.3.217","article-title":"Cortical axonal secretion of bdnf in the striatum is disrupted in the mutant-huntingtin knock-in mouse model of Huntington's disease","volume":"27","author":"Park","year":"2018","journal-title":"Exp Neurobiol"},{"key":"R23-20250607","article-title":"Overview and principles of treatment","author":"Rosenblatt","year":"2011","journal-title":"A Physician's Guide to the Management of Huntington's Disease"},{"issue":"24","key":"R24-20250607","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","article-title":"Targeting huntingtin expression in patients with Huntington's disease","volume":"380","author":"Tabrizi","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"R25-20250607","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1474-4422(17)30280-6","article-title":"Therapies targeting DNA and RNA in Huntington's disease","volume":"16","author":"Wild","year":"2017","journal-title":"Lancet Neurol"},{"issue":"3","key":"R26-20250607","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.stemcr.2017.01.022","article-title":"Reversal of phenotypic abnormalities by CRISPR\/Cas9-mediated gene correction in Huntington disease patient-derived induced pluripotent stem cells","volume":"8","author":"Xu","year":"2017","journal-title":"Stem Cell Reports"}],"container-title":["JAAPA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/01.JAA.0000735740.95438.60","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T19:01:47Z","timestamp":1749322907000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/01.JAA.0000735740.95438.60"}},"subtitle":["A guide to Huntington disease"],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/01.jaa.0000735740.95438.60","relation":{},"ISSN":["1547-1896"],"issn-type":[{"type":"print","value":"1547-1896"}],"subject":[],"published":{"date-parts":[[2021,4]]}}}